Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Innovent Biologics (Suzhou) Co. Ltd.
Age
18–75
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Untreated CD20-positive DLBCL confirmed by histopathology or cytology.
18 years to 75 years; Male or female patients.
International Prognostic Index (IPI) score of 0 to 2.
Signed an informed consent.
At least one measurable lesions: for nodal tumor mass, more than 1.5 cm in the long axis and more than 1.0 cm in the short axis; for extranodal tumor mass, more than 1.0 cm in the long axis.
Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2.
More than 6 months life expectancy.
You may not be if
Participation in another interventional clinical trial in the past 3 months.
Known allergic reactions against monoclonal antibody or rituximab.
Contraindication to any component of CHOP regimen.
Previous treatment for DLBCL, including chemotherapy, immunotherapy, partial radiotherapy for lymphoma, or surgical treatment (excluding tumor mass biopsies and surgical resection for non-lymphoma lesions), or prior use of any monoclonal antibody within 3 month.
History of cytotoxic drugs treatment or anti-CD20 monoclonal antibody treatment for other disease (e.g., rheumatoid arthritis).
Primary central nervous system (CNS) lymphoma, secondary CNS involvement, primary testicular lymphoma.
Clareo Health | A Study Comparing the Efficacy and Safety Between I-CHOP and R-CHOP in Untreated CD20-Positive Diffuse Large B-cell Lymphoma Patients
